


# MEET THE EXPERT



**Robert H Getzenberg**, Ph.D. is currently the Therapeutic Area Lead, Prostate Cancer at GTx Inc. In this role he directs the prostate cancer research efforts including the development of novel selective androgen receptor degraders (SARDs) as well as the study of a selective estrogen receptor alpha agonist. Prior to this position he served as the Director of Research of the James Buchanan Brady Urological Institute and the Donald S Coffey Professor of Urology and Professor of Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine. He also served as Co-Director of the Prostate Cancer Program at the Sidney Kimmel Comprehensive Cancer Center.

Dr. Getzenberg received his Ph.D. from the Johns Hopkins University School of Medicine in 1992 under the tutelage of Dr. Donald S Coffey. He then completed a post-doctoral fellowship at the Yale University School of Medicine. After completing his fellowship, Dr. Getzenberg joined the University of Pittsburgh as an Assistant Professor but eventually was named the Director of Urology Research and a Professor of Urology, Pathology and Pharmacology. At both the Johns Hopkins University and University of Pittsburgh School of Medicines, Dr. Getzenberg served in leadership roles in their respective graduate programs. He has educated and worked with fellows, residents, graduate and undergraduate students throughout his career. Education of the next generation of urology researchers is one of his upmost priorities.

Dr. Getzenberg is the recipient of a number of awards including the 2000 University of Pittsburgh chancellor's Distinguished Research Award and was selected as one of the "40 under 40" by Pittsburgh Magazine. He is the recipient of a number of grants from the National Institutes of Health and other agencies and foundations including the Prostate Cancer Foundation. Dr. Getzenberg has given numerous international lectures related to his work including the first Donald Gleason Lecture at the University of Minnesota in 2012 and the Weisbach Lecture at the University of Michigan in 2007. He has also served as the keynote speaker at urology and oncology meetings in Japan, China and throughout Europe. Dr. Getzenberg has and continues to serve in many leadership positions in urology research. He served as Treasurer and President of the Society of Basic Urologic Research and in many research capacities at the American Urological Association. Dr. Getzenberg has authored a large number of manuscripts and book chapters in the field.

Dr. Getzenberg's major research interests revolve around novel therapeutic approaches to urologic diseases with a particular focus on prostate cancer. These are centered on the implementation of tools with which to personalize the therapeutic pathway for individual patients. As therapeutic approaches, specific interests include selective androgen receptor degraders (SARDs), estrogenic compounds and targeting the environmental fitness of cancer cells. The Cancer/Testis Antigens are a major area of interest both as biomarkers as well as potential therapeutic targets.

## Relation to AJA

The AJA, with its focus on a broader scope of andrology, fulfills a unique need in our field. The quality of the articles is outstanding and many of these address research questions from unique perspectives. One of the most valuable tools is the "special issue" which provides for a comprehensive and contemporary analysis of an important question or topic. Under Professor Wang and his incredible staff, the AJA has become a leading source for cutting edge research and an important reference for us all.